Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation

Transplant Infectious Disease

Volumn 12, Issue 3, 2010, Pages 261-264

  Mousset, S ^a   Bug, G ^a   Heinz, W J ^b   Tintelnot, K ^c   Rickerts, V ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Antifungal prophylaxis; Breakthrough infection; Graft versus host disease; Posaconazole; Stem cell transplant; Zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CASPOFUNGIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; POSACONAZOLE; PREDNISOLONE; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE REPORT; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HUMAN; HUMAN TISSUE; INFECTIOUS PNEUMONIA; LUNG HEMORRHAGE; MALE; PANCYTOPENIA; PRIORITY JOURNAL; RHIZOPUS; RHIZOPUS MICROSPORUS; SYSTEMIC MYCOSIS; ZYGOMYCOSIS; ALLOTRANSPLANTATION; CHEMOPROPHYLAXIS; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECTS; FATALITY; GRAFT VS HOST DISEASE; ISOLATION AND PURIFICATION; LUNG DISEASES, FUNGAL; MICROBIOLOGY; MIDDLE AGED; MUCORMYCOSIS; PATHOLOGY; PNEUMONIA; STEM CELL TRANSPLANTATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; FATAL OUTCOME; GRAFT VS HOST DISEASE; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MUCORMYCOSIS; PNEUMONIA; RHIZOPUS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 77953184153     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00479.x     Document Type: Article

References (16)

1. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 347.
2. Schlemmer F, Lagrange-Xelot M, Lacroix C, de La TR, Socie G, Molina JM. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008 42 : 551 552.
3. Schwarz P, Bretagne S, Gantier JC, et al. Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol 2006 44 : 340 349.
4. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
5. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007 27 : 1627 1636.
6. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004 350 : 950 952.
7. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007 40 : 451 456.
8. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007 39 : 425 429.
9. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009 199 : 1399 1406.
10. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008 47 : 503 509.
11. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008 46 : 551 559.
12. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003 47 : 3647 3650.
13. Perkhofer S, Locher M, Cuenca-Estrella M, et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother 2008 52 : 2636 2638.
14. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008 52 : 3786 3788.
15. Rickerts V, Atta J, Herrmann S, et al. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 2006 49 (Suppl 10) : 27 30.
16. Reed C, Ibrahim A, Edwards JE Jr., Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006 50 : 3968 3969.